KOL

Sofwave Medical Reports First Half Financial Results and Business Highlights

Retrieved on: 
Tuesday, August 16, 2022 - 1:30pm

SAN CLEMENTE, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported results for the first half of fiscal year 2022, for the period ended June 30, 2022.

Key Points: 
  • SAN CLEMENTE, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported results for the first half of fiscal year 2022, for the period ended June 30, 2022.
  • IFRS Operating Loss was $9.0M; Non-IFRS $6.3M
    Cash as of June 30, 2022 was $36M
    Mr. Louis Scafuri, Sofwave CEO commented, Sofwave significantly grew revenues 34% in the first half of 2022 while garnering industry accolades for SUPERB lifting and wrinkle reduction technology.
  • We are proud to have more than half of top ranking providers as users of Sofwaves SUPERB medical aesthetic devices.
  • With half of the remaining fiscal reporting period to go, we have also surpassed the number of Sofwave treatments performed for the whole of fiscal 2021.

Four HKTDC August fairs and ICMCM close on a High Note

Retrieved on: 
Monday, August 15, 2022 - 11:00am

The Food Expo, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair drew to a close today, attracting more than 430,000 visitors.

Key Points: 
  • The Food Expo, Home Delights Expo, Beauty & Wellness Expo and Hong Kong International Tea Fair drew to a close today, attracting more than 430,000 visitors.
  • The HKTDC also interviewed around 980 visitors during the fairs through random sampling.
  • 48% of respondents spent HK$1,000 or more at the fairs, with the average per capita spending reaching HK$1,400.
  • For more comments from exhibitors and buyers, please visit:
    - HKTDC Home Delights Expo: https://bit.ly/3C3720E
    - HKTDC Beauty & Wellness Expo: https://bit.ly/3dvJXJP
    - HKTDC Hong Kong International Tea Fair: https://bit.ly/3AouJPU

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 12, 2022 - 12:00pm

MENLO PARK, Calif. and SINGAPORE, Aug. 12, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate activities.

Key Points: 
  • Cash used in operating activities for the second quarter of 2022 was US$9.7 million compared to US$6.9 million in the same period in 2021.
  • Research and development expenses were US$10.0 million in the second quarter of 2022 compared to US$4.0 million in the second quarter of 2021.
  • General and administrative expenses were US$2.3 million in the second quarter of 2022 compared to US$3.8 million in the second quarter of 2021.
  • Net loss attributable to stockholders for the second quarter of 2022 was US$13.0 million compared to a net loss of US$5.4 million for the second quarter of 2021.

Humacyte Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Friday, August 12, 2022 - 12:00pm

-- Conference call and live webcast at 8:00 a.m. ET today –

Key Points: 
  • ET today
    DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
  • Early in the second quarter, Humacyte launched an initiative to provide its HAVs to hospitals in Ukraine for the treatment of wounded civilians and soldiers with vascular trauma injuries.
  • Revenue was $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021, and was $1.5 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021.
  • Other net income was $55.4 million for the second quarter of 2022, compared to $2.1 million for the second quarter of 2021, and was $57.3 million for the six months ended June 30, 2022, compared to $1.5 million for the six months ended June 30, 2021.

HTG Molecular Diagnostics Reports Second Quarter 2022 Results

Retrieved on: 
Thursday, August 11, 2022 - 9:05pm

TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June30, 2022.

Key Points: 
  • TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June30, 2022.
  • Second Quarter 2022 Financial Highlights:
    Revenue for the quarter ended June30, 2022 was $1.5 million, compared with $2.1 million for the same period in 2021, and was comprised entirely of product and product-related services revenue.
  • Net loss from operations for the quarter ended June30, 2022 was $5.7 million, compared with $4.1 million for the same period in 2021.
  • Net loss per share was $(0.54) for the quarter ended June30, 2022 compared with $(0.39) for the second quarter of 2021.

H1 Launches AI-Powered and Evidence-Based Interactions to Meet the Evolving Needs of Pharmaceutical and Biotech Medical Affairs Teams

Retrieved on: 
Thursday, August 11, 2022 - 2:00pm

The role of Medical Affairs teams has shifted from specializing in products and diseases to being stewards of scientific discourse and outcomes-based information, said Ariel Katz, co-founder and CEO of H1.

Key Points: 
  • The role of Medical Affairs teams has shifted from specializing in products and diseases to being stewards of scientific discourse and outcomes-based information, said Ariel Katz, co-founder and CEO of H1.
  • Pharmaceutical and medical device companies can establish more efficient workflows, identify market signals that impact strategic decisions, and help medical field teams optimize every HCP engagement.
  • HCP Universe is built on the H1 Connect platform , which seamlessly blends H1 proprietary, public, industry, and self-reported HCP information and patient encounter data.
  • The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors.

AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases

Retrieved on: 
Thursday, August 11, 2022 - 12:30pm

Management will also discuss the advantages offered by the innovative biomarker-based clinical trial designs being utilized in its Alzheimers and Parkinsons disease programs.

Key Points: 
  • Management will also discuss the advantages offered by the innovative biomarker-based clinical trial designs being utilized in its Alzheimers and Parkinsons disease programs.
  • Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer's disease.
  • AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, NO and RU.

IMV Inc. Announces Second Quarter 2022 Financial and Operational Results

Retrieved on: 
Thursday, August 11, 2022 - 12:05pm

IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.

Key Points: 
  • IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.
  • IMV continues to enroll patients in the VITALIZE Phase 2B clinical trial, advancing its lead compound, maveropepimut-S (MVP-S) in a global, multi-center confirmatory trial.
  • IMV is on track to complete enrollment of the first stage of the study in H1 2023.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, August 11, 2022 - 12:00pm

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
  • We continued to achieve great progress for Aravive in the second quarter of 2022.
  • Our Phase 1b trial in pancreatic cancer has completed enrollment and updated results are anticipated later this year.
  • Revenues for the three months ended June 30, 2022 were $1.6 million, compared to $1.1 million for the three months ended March 31, 2022.

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

Retrieved on: 
Wednesday, August 10, 2022 - 9:05pm

On July 28, 2022, Femasys hosted a Key Opinion Leader (KOL) event in the wake of the overturn of Roe v. Wade, to discuss FemBloc.

Key Points: 
  • On July 28, 2022, Femasys hosted a Key Opinion Leader (KOL) event in the wake of the overturn of Roe v. Wade, to discuss FemBloc.
  • An interim analysis for the FemaSeed LOCAL de novo pivotal trial is planned for the fourth quarter of this year.
  • Gross margin percentage was 66.2% for the three months ended June 30, 2022 as compared to 67.0% for the three months ended June 30, 2021.
  • Gross margin percentage was 64.0% for the six months ended June 30, 2022 as compared to 69.4% for the six months ended June 30, 2021.